Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.…
Nuwellis to Host Webinar Discussing ULTRA-Peds Registry Results and Aquadex Performance in Critically Ill Pediatric Patients
Nuwellis (NASDAQ: NUWE) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 38 employees.
The shares were at 3.410 USD on 20 November 2026, down 99.6% over 52 weeks. Its 52-week range is 2.525 USD to 1556.10 USD: the price is 99.8% below the high and 35.1% above the low.
Its market capitalisation is 1.84M USD.
Nuwellis reports an operating margin of -142.9% and revenue up 14.1% year over year.
It holds more cash than debt, a net cash position of 3.72M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 9 March 2027.